Amgen Inc. (NASDAQ:AMGN) Shares Sold by Sittner & Nelson LLC

by · The Cerbat Gem

Sittner & Nelson LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.6% during the third quarter, Holdings Channel reports. The institutional investor owned 7,272 shares of the medical research company’s stock after selling 116 shares during the period. Amgen makes up 1.0% of Sittner & Nelson LLC’s portfolio, making the stock its 20th biggest holding. Sittner & Nelson LLC’s holdings in Amgen were worth $2,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Trinity Legacy Partners LLC boosted its stake in shares of Amgen by 1.6% during the 3rd quarter. Trinity Legacy Partners LLC now owns 15,382 shares of the medical research company’s stock valued at $4,993,000 after buying an additional 239 shares during the last quarter. Tandem Investment Advisors Inc. boosted its stake in Amgen by 107.4% in the third quarter. Tandem Investment Advisors Inc. now owns 1,655 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 857 shares during the period. Dudley Capital Management LLC acquired a new position in Amgen during the 3rd quarter valued at approximately $303,000. ARK Investment Management LLC grew its position in shares of Amgen by 2.4% during the third quarter. ARK Investment Management LLC now owns 76,614 shares of the medical research company’s stock worth $24,686,000 after acquiring an additional 1,793 shares during the last quarter. Finally, Consolidated Planning Corp grew its position in Amgen by 273.7% in the 3rd quarter. Consolidated Planning Corp now owns 2,515 shares of the medical research company’s stock worth $811,000 after purchasing an additional 1,842 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on AMGN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. UBS Group decreased their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Bank of America boosted their price target on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Robert W. Baird reissued an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. Finally, Sanford C. Bernstein started coverage on Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $333.50.

Check Out Our Latest Report on Amgen

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $321.91 on Friday. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The firm has a market capitalization of $173.04 billion, a PE ratio of 41.22, a P/E/G ratio of 2.79 and a beta of 0.60. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a 50-day moving average price of $323.96 and a two-hundred day moving average price of $316.68.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.96 EPS. Equities analysts forecast that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).